KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -48.59% | -16.97% | -67.11% | -- |
| Total Depreciation and Amortization | -- | 12.50% | 19.18% | 10.63% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 334.86% | -99.51% | 338.43% | -- |
| Change in Net Operating Assets | -- | -103.42% | -30.53% | 641.96% | -- |
| Cash from Operations | -- | -35.51% | -167.22% | -18.53% | -99.96% |
| Capital Expenditure | -- | -1,280.95% | -1,773.33% | -26.32% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -42.04% | 97.59% | 227.80% | -- |
| Cash from Investing | -- | -42.79% | 97.36% | 227.08% | 70.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -57.03% | -98.09% | 19,809.51% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -94.71% | -- | -- |
| Cash from Financing | -- | 673.67% | -96.90% | 53,341.20% | 130.47% |
| Foreign Exchange rate Adjustments | -- | 2,227.35% | 4,645.95% | -101.13% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -12,486.44% | -508.44% | 465.10% | 17.88% |